查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1624999

2024 年至 2031 年黏弹性补充剂市场规模（按产品类型、材料类型、应用、最终用户、分销管道和地区划分）

Viscosupplementation Market Size by Product Type, Material Type, Application, End-User, Distribution Channel & Region for 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

黏液补充市场评估，2024-2031 年

由于骨关节炎和其他关节疾病的发生率不断上升，黏弹性补充剂市场正在扩大。随着医疗保健提供者扩大采用这些治疗方法来缓解疼痛和改善关节功能，基于透明质酸的产品的创新正在推动需求。因此，预计 2024 年市场规模将超过 65 亿美元，到 2031 年将达到约 123.8 亿美元。

此外，随着老龄化人口的扩大，对手术以外治疗选择的需求也日益增长。此外，黏弹性补充疗法作为一种微创治疗方法越来越受到寻求替代传统关节手术的患者欢迎。由于关节内置换治疗的需求不断增长，预计 2024 年至 2031 年期间市场复合年增长率为 9.24%。

定义/概述

黏弹性补充疗法是一种将透明质酸注入关节以增加润滑和缓衝的治疗方法。它主要用于控制骨关节炎患者的疼痛和改善其活动能力。

它主要用于透过增加滑液来缓解关节疼痛，尤其是膝盖疼痛。这种非手术治疗方法在治疗中度关节炎方面越来越受欢迎，并被广泛采用。

未来前景包括透明质酸配方的不断进步，从而带来更好的效果。人口老化和对非侵入性治疗的需求不断增长，促进了黏液补充市场的潜在扩张。

范例下载

骨关节炎盛行率的不断上升如何推动黏弹性补充剂市场的成长？

骨关节炎盛行率的不断上升对有效的疼痛管理解决方案产生了更高的需求，从而极大地推动了黏弹性补充剂市场的成长。随着越来越多的人寻求缓解关节疼痛和提高活动能力，医疗保健提供者扩大采用黏液补充疗法。这种微创选择为手术介入提供了可行的替代方案，并将吸引寻求有效但微创方法的患者。因此，这一趋势正在支持整个市场的扩张。

黏液补充疗法的高成本会阻碍市场成长吗？

黏液补充疗法的高成本限制了许多患者能够接受该疗法，对市场的成长构成了重大课题。保险覆盖范围的差异进一步加剧了这个问题，因为并非所有保险计划都提供足够的报销。因此，患者可以选择更实惠的替代疗法，从而减少对黏液补充的需求。这些经济障碍将阻碍医疗保健提供者的采用，并最终影响黏液补充市场的整体成长和潜力。

目录

第 1 章 全球黏弹性补充市场简介

  • 市场介绍
  • 调查范围
  • 先决条件

第 2 章执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

  • 数据挖掘
  • 验证
  • 一次资料
  • 数据源列表

第4章 关节置换治疗的全球市场展望

  • 概述
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力模型
  • 价值链分析

第 5 章 全球黏液补充品市场（按类型）

  • 概述
  • 单次注射黏弹性补充疗法
  • 三次注射黏弹性补充疗法
  • 五次注射黏弹性补充疗法

第6章全球关节黏液补充剂市场（按应用）

  • 概述
  • 膝关节骨关节炎
  • 髋关节骨关节炎
  • 肩部骨关节炎

第7章 关节黏液补充市场（依最终用户划分）

  • 概述
  • 医院
  • 骨科诊所/门诊手术中心
  • 零售药店

第8章 全球黏液补充市场（按地区）

  • 概述
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 世界其他地区
    • 拉丁美洲
    • 中东/非洲

第9章 全球黏液补充市场：竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第10章 公司简介

  • Sanofi
  • Anika Therapeutics, Inc.
  • Seikagaku Corp.
  • Zimmer Biomet
  • Smith & Nephew PLC
  • Ferring Pharmaceuticals B.V.
  • Lifecore Biomedical
  • LG Life Sciences Ltd.
  • Fidia Farmaceutici S.p.A
  • F.Hoffmann-La Roche Ltd.

第 11 章 附录

  • 相关研究
简介目录
Product Code: 25768

Viscosupplementation Market Valuation- 2024-2031

The Viscosupplementation Market is increasing due to the rising prevalence of osteoarthritis and other joint disorders. Innovations in hyaluronic acid-based products are driving demand, with healthcare providers increasingly adopting these treatments for pain relief and joint function improvement. This is likely to enable the market size to surpass USD 6.5 Billion valued in 2024 to reach a valuation of aroundUSD 12.38 Billion by 2031.

Additionally, the market is seeing growth from the expanding aging population, which is driving the need for non-surgical options. Moreover, increasing awareness about viscosupplementation as a minimally invasive treatment is contributing to its popularity among patients seeking alternatives to traditional joint surgeries. The rising demand for viscosupplementation is enabling the market to grow at aCAGR of 9.24% from 2024 to 2031.

Definition/Overview

Viscosupplementation is a medical treatment involving hyaluronic acid injections into joints, increasing lubrication and cushioning. It is primarily used to manage pain and improve mobility in osteoarthritis patients.

Its use is focused on alleviating joint pain, particularly in the knee, by increasing synovial fluid. This non-surgical option is increasingly popular for managing moderate arthritis cases, driving adoption.

Future scope includes increasing advancements in hyaluronic acid formulations, driving better outcomes. The aging population and increasing demand for non-invasive treatments are contributing to the expanding market potential for viscosupplementation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Is the Increasing Prevalence of Osteoarthritis Driving the Growth Of The Viscosupplementation Market?

The increasing prevalence of osteoarthritis significantly drives the growth of the Viscosupplementation market by creating a higher demand for effective pain management solutions. As more individuals seek relief from joint pain and improved mobility, healthcare providers increasingly adopt viscosupplementation treatments. These minimally invasive options offer a viable alternative to surgical interventions, appealing to patients looking for effective yet less invasive approaches. Consequently, this trend supports the expansion of the market overall.

How Does the High Cost of Viscosupplementation Treatments Challenge the Growth of The Market?

The high cost of Viscosupplementation treatments poses a significant challenge to market growth by limiting accessibility for many patients. Insurance coverage discrepancies further exacerbate this issue, as not all plans provide adequate reimbursement. Consequently, patients may opt for alternative, more affordable treatments, reducing demand for viscosupplementation. This financial barrier can hinder widespread adoption among healthcare providers, ultimately impacting the overall expansion and potential of the viscosupplementation market.

Category-wise Acumens

How Will the Increasing Effectiveness of Hyaluronic Acid in Pain Management Drive the Growth of The Hyaluronic Acid-Based Product Segment?

The increasing effectiveness of hyaluronic acid in pain management will drive the growth of the hyaluronic acid-based product segment in the Viscosupplementation Market. Its ability to improve joint lubrication and mobility, particularly in osteoarthritis patients, makes it a preferred treatment option. As more healthcare providers and patients recognize its benefits in offering long-lasting relief without surgery, demand for hyaluronic acid-based products will continue to expand, supporting this segment's growth.

How Will the Growing Preference for Minimally Invasive Procedures Drive the Growth Of The Single Injection Segment?

The growing preference for minimally invasive procedures will drive the growth of the single injection segment in the Viscosupplementation Market. Single injections offer a simpler, less invasive option for osteoarthritis patients, reducing the number of hospital visits and overall discomfort. This convenience appeals to both patients and healthcare providers, enhancing its adoption. As the demand for efficient and patient-friendly treatments increases, the single injection segment is positioned for significant growth.

Country/Region-wise Acumens

Will The High Prevalence of Osteoarthritis and Advanced Healthcare Infrastructure Drive the Dominance of North America in The Viscosupplementation Market?

The high prevalence of osteoarthritis and advanced healthcare infrastructure will drive the dominance of North America in the Viscosupplementation Market. With a significant aging population, the demand for effective pain management solutions is increasing. Moreover, the region's robust healthcare system supports innovation and adoption of new treatments, allowing for better patient outcomes. The presence of leading manufacturers and strong research initiatives further enhances North America's position as a key player in this market.

Will Rising Awareness of Osteoarthritis Treatments Drive the Rapid Growth of The Asia-Pacific Region in The Viscosupplementation Market?

Increasing healthcare expenditures and rising awareness of osteoarthritis treatments will drive the rapid growth of the Asia-Pacific region in the viscosupplementation market. As more individuals become aware of effective pain management options, demand for these therapies is expected to rise. Improved healthcare infrastructure facilitates access to innovative treatments, making them more widely available. Additionally, the growing aging population in this region further contributes to the increasing need for viscosupplementation solutions, supporting market expansion.

Competitive Landscape

The viscosupplementation market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the viscosupplementation market include:

Sanofi S.A.

Anika Therapeutics, Inc.

Seikagaku Corporation

Zimmer Biomet Holdings Inc.

Smith & Nephew PLC

Ferring Pharmaceuticals B.V.

Lifecore Biomedical

Fidia Farmaceutici S.p.A.

Bioventus LLC

Johnson & Johnson Services, Inc.

Latest Developments

In September 2024, Sanofi S.A. announced a licensing agreement with RadioMedix and Orano Med for a next-generation radioligand medicine aimed at treating rare cancers, showcasing its commitment to innovative cancer therapies.

In March 2023, Seikagaku Corporation launched Hyalgan G-F 20 in Japan, a new formulation of hyaluronic acid designed for knee osteoarthritis, enhancing its product portfolio in the viscosupplementation market.

In April 2023, Zimmer Biomet Holdings Inc. received FDA 510(k) clearance for their Persona Knee Hyaluronic Acid, which is intended to provide pain relief for patients suffering from knee osteoarthritis, reflecting their focus on advancing treatment options.

In October 2023, Anika Therapeutics, Inc. reported positive results from a Phase 3 study of Qsymia, aimed at alleviating knee osteoarthritis pain, reinforcing its position in the development of effective non-surgical treatments for joint pain.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VISCOSUPPLEMENTATION MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL VISCOSUPPLEMENTATION MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL VISCOSUPPLEMENTATION MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Single Injection Viscosupplementation
  • 5.3 Three Injection Viscosupplementation
  • 5.4 Five Injection Viscosupplementation

6 GLOBAL VISCOSUPPLEMENTATION MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Knee Osteoarthritis
  • 6.3 Hip Osteoarthritis
  • 6.4 Shoulder Osteoarthritis

7 GLOBAL VISCOSUPPLEMENTATION MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Orthopedic Clinics/ Ambulatory Surgical Centers
  • 7.4 Retail Pharmacies

8 GLOBAL VISCOSUPPLEMENTATION MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL VISCOSUPPLEMENTATION MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Sanofi
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Anika Therapeutics, Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Seikagaku Corp.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Zimmer Biomet
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Smith & Nephew PLC
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Ferring Pharmaceuticals B.V.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Lifecore Biomedical
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 LG Life Sciences Ltd.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Fidia Farmaceutici S.p.A
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 F.Hoffmann-La Roche Ltd.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research